


The background features a complex, abstract pattern. On the left side, there are concentric circles composed of many small, colored squares in shades of blue, teal, and brown. These circles radiate from a central point. To the right of these circles, the squares are scattered more randomly across the dark gray background. A solid white circle is positioned in the upper right corner of the image.

Market Assessment of Orphan Drugs

By

Dikshita Hatwar (0237)

Under the guidance of

Dr. Rahul Sharma

About the Organization



ZS Associates is a management consulting and professional services firm focusing on consulting, software and technology, headquartered in Evanston, Illinois that provides services for clients in private equity, healthcare, and technology



The firm was founded in 1983 by two professors at Northwestern University who developed sales force alignment models using the world's first personal computer- aided territory mapping system



The firm employs more than 7,000 employees in 24 offices in North America, South America, Europe and Asia

OVERVIEW

Orphan drugs are highly pharmacological agents with specialized functions used to treat rare (orphan) diseases. The global orphan medicines market was worth \$1,40,000.0 million in 2020 and is anticipated to arrive \$4,35,686.3 million by 2030

A rare disorder in the US is one that affects less than 200,000 persons overall


A condition is considered to be rare in the European Union (EU) if it affects fewer than 1 in 2,000 people

EXTENT OF THE STUDY:

- *Importance of Orphan drugs*
- *New and upcoming drugs*
- *Market size of orphan drugs*
- *About NORD*
- *Policy reforms*

OBJECTIVE

To investigate competitive landscape of the orphan medicines market by analyzing leading market competitors and their tactics



To an in-depth examination of the global orphan pharmaceuticals market, as well as current trends and forecasts for the future perform



STUDY DESIGN

Descriptive study review through qualitative and quantitative secondary research



DURATION OF STUDY

The study duration is 3 months from March – June 2022



SETTING OF THE STUDY

Global market is being considered under study of orphan drugs. The study is conducted from India



DATA COLLECTION PROCEDURE

Secondary research based on internet-available literature. The data gathered from different research articles




SOURCES OF DATA


Secondary research

METHODOLOGY


WORLDWIDE ORPHAN DRUG SALES



Top 10 companies and total market



Sales %



Top 3 therapeutic category for orphan (rare) drugs -

- 1. Cancer**
- 2. Blood disorders**
- 3. CNS**

■ Oncology

■ Blood

■ CNS

■ Various

■ Respiratory

■ Cardiovascular

■ Musculoskeletal

■ Immunomodulators

■ Endocrine

■ Systemic Anti-infectives

■ Gastro-intestinal

■ Dermatology

The global orphan medicines market was worth \$1,40,000.0 million in 2020 and is anticipated to arrive \$4,35,686.3 million by 2030

In terms of disease category, the oncology segment dominated the global market for orphan products in 2020

The growth of orphans is anticipated to continue being fueled by the development of new tools and methods for finding drugs, from gene editing to AI-assisted drug discovery and development

In terms of countries, North America is anticipated to develop at the fastest rate, registering a CAGR of 11.0 percent over the projected period for the orphan medicines market

North America represented the highest percentage of the worldwide orphan drugs market in 2020 and is predicted to stay dominant during the forecast period. This was attributed to presence of large patient pool and early adoption of advance drugs, strong presence of key players, availability of drugs, early diagnosis, and favorable compensation policies

CONCLUSION